1. Home
  2. SLN vs QUAD Comparison

SLN vs QUAD Comparison

Compare SLN & QUAD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • SLN
  • QUAD
  • Stock Information
  • Founded
  • SLN 1994
  • QUAD 1971
  • Country
  • SLN United Kingdom
  • QUAD United States
  • Employees
  • SLN N/A
  • QUAD N/A
  • Industry
  • SLN Biotechnology: Pharmaceutical Preparations
  • QUAD Publishing
  • Sector
  • SLN Health Care
  • QUAD Consumer Discretionary
  • Exchange
  • SLN Nasdaq
  • QUAD Nasdaq
  • Market Cap
  • SLN 352.2M
  • QUAD 408.6M
  • IPO Year
  • SLN N/A
  • QUAD 2010
  • Fundamental
  • Price
  • SLN $4.79
  • QUAD $6.00
  • Analyst Decision
  • SLN Buy
  • QUAD Strong Buy
  • Analyst Count
  • SLN 4
  • QUAD 2
  • Target Price
  • SLN $46.25
  • QUAD $10.15
  • AVG Volume (30 Days)
  • SLN 339.1K
  • QUAD 335.2K
  • Earning Date
  • SLN 02-27-2025
  • QUAD 02-18-2025
  • Dividend Yield
  • SLN N/A
  • QUAD 3.76%
  • EPS Growth
  • SLN N/A
  • QUAD N/A
  • EPS
  • SLN N/A
  • QUAD N/A
  • Revenue
  • SLN $21,773,221.00
  • QUAD $2,672,200,000.00
  • Revenue This Year
  • SLN N/A
  • QUAD N/A
  • Revenue Next Year
  • SLN $104.98
  • QUAD N/A
  • P/E Ratio
  • SLN N/A
  • QUAD N/A
  • Revenue Growth
  • SLN N/A
  • QUAD N/A
  • 52 Week Low
  • SLN $4.06
  • QUAD $4.06
  • 52 Week High
  • SLN $27.72
  • QUAD $9.13
  • Technical
  • Relative Strength Index (RSI)
  • SLN 41.33
  • QUAD 40.04
  • Support Level
  • SLN $4.71
  • QUAD $6.57
  • Resistance Level
  • SLN $5.16
  • QUAD $8.04
  • Average True Range (ATR)
  • SLN 0.47
  • QUAD 0.64
  • MACD
  • SLN 0.08
  • QUAD -0.06
  • Stochastic Oscillator
  • SLN 32.74
  • QUAD 1.92

About SLN Silence Therapeutics Plc American Depository Share

Silence Therapeutics PLC is a biotechnology company focused on discovering and developing novel molecules incorporating short-interfering ribonucleic acid. its pipeline products are; SLN360 therapy designed to temporarily block a specific gene's message that would otherwise trigger an unwanted effect. By silencing the LPA gene, the levels of Lp(a) are lowered, which in turn is expected to lower the risks of heart diseases, heart attacks, and strokes, and SLN124 therapy aims to temporarily silence TMPRSS6, a gene that prevents the liver from producing a particular hormone that controls iron levels in the body hepcidin. As hepcidin increases, iron levels in the blood are expected to decrease, which may increase the production of healthy red blood cells, thereby reducing anemia.

About QUAD Quad Graphics Inc

Quad/Graphics Inc provides print and marketing services to help customers market their products, services, and contents. The company operates in the commercial segment of the printing industry. It operates through three divisions. The United States print and related services segment consists of the company's American operations. Besides the complete set of print and marketing solutions, this segment also manufactures ink. The international segment includes the company's printing business in Europe and Latin America. The corporate segment is engaged in the general and administrative activities as well as associated costs. The company almost generates all its revenue from the American domestic market.

Share on Social Networks: